



IMCage

Atty. Dkt. No. 053466-0391

Applicant: Kiichiro YANO et al.
Title: ANTI-AGING PREPARATION
Appl. No.: 10/518,915 /
Filing Date: 12/23/2004
Examiner: Unassigned
Art Unit: 1617

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

Some documents listed on the attached Form PTO/SB/08 were cited as being relevant during the prosecution of the corresponding International application. A copy of the International Search Report is attached setting forth the portion of each document considered relevant by the examiner. English language abstracts have been provided herewith.

Document A8 discloses an anti-aging agents which promote production of collagen and inhibits elastase activity.

Document A12 discloses certain plant extracts as promoters for production of hyaluronic acid which are effective in preventing the aging of human skin.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date July 5, 2005


FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

By 

for Stephen B. Maebius *Matthew E. Mulkeen*
Attorney for Applicant *Reg No 44,250*
Registration No. 35,264

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/518,915
		Filing Date	12/23/2004
Date Submitted: July 5, 2005 (use as many sheets as necessary)		First Named Inventor	Kiichiro YANO
		Group Art Unit	1617
Sheet 1 of 2		Examiner Name	Unassigned
		Attorney Docket Number	053466-0391

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	5,837,224		Voorhees et al.	11/17/1998	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A2	JP	61-161208		Nisshin Oil Mills, Ltd.	07/21/1986		Abs
	A3	JP	1-117815		Pola Chem Ind Inc.	05/10/1989		Abs
	A4	JP	6-24937		Narisu Keshohin KK	02/01/1994		Abs
	A5	JP	9-221410		Noevir Co. Ltd.	08/26/1997		Abs
	A6	JP	10-330222		Pola Chem Ind Inc.	12/15/1998		Abs
	A7	JP	11-12122		Pola Chem Ind Inc.	01/19/1999		Abs
	A8	JP	11-335235		Shiseido Co. Ltd.	12/07/1999		Abs
	A9	JP	2001-31521		Ichimaru Pharcos Co. Ltd.	02/06/2001		Abs
	A10	JP	2001-115197		Take KK	04/24/2001		Abs
	A11	JP	2001-139484		Lion Corp.	05/22/2001		Abs
	A12	JP	2001-163794		Shiseido Co Ltd.	06/19/2001		Abs
	A13	JP	2001-181169		Kao Corp.	07/03/2001		Abs
	A14	JP	2001-226218		Ichimaru Pharcos Co Ltd.	08/21/2001		Abs
	A15	JP	2001-333731		Ichimaru Pharcos Co Ltd.	12/04/2001		Abs
	A16	PCT	WO 02/34885	A1	National Institute of Agrobiological Sciences	03/22/2001		Abs

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A17	ISHIJIMA, Saori et al., "To Keep Skin Young: Tales of a High-Molecular Component, Kobunshi, 1995, Vol. 44, No. 6, pgs. 362-364.	
	A18	METORI, Koichi et al., "The Preventive Effect of Ginseng with Du-Zhong Leaf on Protein Metabolism in Aging", <i>BIOL. PHARM. BULL.</i> , 1997, Vol. 20, No. 3, pgs. 237-242.	
	A19	MOCHIZUKI, Mami et al., "Inhibitory Effect of Tumor Metastasis in Mice by Saponins, Ginsenoside-Rb2, 20(R)- and 20(S)-Ginsenoside-Rg3, of Red ginseng", <i>BIOL. PHARM. BULL.</i> , 1995, Vol. 18, No. 9, pgs. 1197-1202.	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/518,915
		Filing Date	12/23/2004
		First Named Inventor	Kiichiro YANO
		Group Art Unit	1617
		Examiner Name	Unassigned
Date Submitted: July 5, 2005		Attorney Docket Number	053466-0391
(use as many sheets as necessary)			
Sheet	2	of	2



NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A20	MORISAKI, Nobuhiro, "Kekkan Shinsei to Yakuyo Ninjin", <i>BIOMEDICINE & THERAPEUTICS</i> , Vol. 28, No. 1, pgs. 94-95.	
	A21	SATO, Katsuaki et al., "Inhibition of Tumor Angiogenesis and Metastasis by a Saponin of <i>Panax ginseng</i> , Ginsenoside-Rb2", <i>BIOL. PHARM. BULL.</i> , 1994, Vol. 17, No. 5, pgs. 635-639.	
	A22	TAMURA, Hiroaki et al., "New Cosmetic Ingredients having Anti-aging", <i>FRAGRANCE JOURNAL</i> , 2000, Vol. 28, No. 12, pgs. 38-42, (pg. 40/3-2).	
	A23	TANAKA, Hiroshi et al., "Effect of panax ginseng on the production of glycoaminoglycans in cultured human skin fibroblast", <i>FRAGRANCE JOURNAL</i> , 1991, Vol. 28, No. 1, pgs. 90-92.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.